Disc MedicineNASDAQ: IRON

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 August 2020

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.91 B
0%vs. 3y high
80%vs. sector
-vs. 3y high
-vs. sector
-28%vs. 3y high
76%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 1 min ago
$64.28+$4.79(+8.04%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

IRON Latest News

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
globenewswire.com25 October 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive additional data from an ongoing Phase 1b study of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia, including results from the 40 mg and 60 mg single ascending dose (SAD) cohorts. The data presented at the 2024 American Society of Nephrology (ASN) Kidney Week in San Diego, CA demonstrated that a single dose of DISC-0974 results in sustained suppression of hepcidin and mobilization of iron, and increased erythropoiesis and levels of hemoglobin in NDD-CKD patients with anemia.

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
globenewswire.com11 October 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced upcoming clinical data to be presented at the 2024 American Society of Nephrology (ASN) Kidney Week, which will be held in San Diego, CA on October 24-27, 2024. The poster will report on additional SAD cohorts from the Phase 1b, randomized, placebo-controlled study of DISC-0974 in patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia. This study was designed to assess safety as well as changes to hepcidin, iron, and key hematologic parameters.

Disc Medicine to Participate in Upcoming Investor Conferences
globenewswire.com30 August 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

LEADING FINTECH MONEYTHUMB ACQUIRED BY IRON CREEK
prnewswire.com29 August 2024 Sentiment: POSITIVE

Partnership to Accelerate Future Growth and Innovation of MoneyThumb's SaaS Document Evaluation Technology SAN DIEGO , Aug. 29, 2024 /PRNewswire/ -- MoneyThumb, a leader in automated document evaluation and fraud detection solutions announced today that it has been acquired by Iron Creek Partners LLC ("Iron Creek"), a private investment firm with a focus on investments in the software, data, communications, and business services industries. Iron Creek led the investment group, which also included Main Street Capital Corporation (NYSE: MAIN).

Disc Medicine Announces Underwritten Offering of Common Stock
globenewswire.com14 June 2024 Sentiment: POSITIVE

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share. The aggregate gross proceeds to Disc from this offering are expected to be approximately $178.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities being sold in the offering are being offered by Disc. The offering is expected to close on June 17, 2024, subject to the satisfaction of customary closing conditions.

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
globenewswire.com14 June 2024 Sentiment: POSITIVE

WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive additional data for bitopertin in erythropoietic protoporphyria (EPP), including additional analyses of AURORA data that further demonstrated the clinical activity of bitopertin and highlighted meaningful improvements in light tolerance, phototoxic reactions, and quality of life. Additionally, Disc shared updated data from a Phase 1b trial of DISC-0974 in MF anemia which demonstrated durable increases in hemoglobin and reduced transfusion burden in a majority of evaluable patients. Disc also shared initial SAD data from a Phase 1 healthy volunteer trial of DISC-3405 that provided proof of mechanism, showing that the drug has the potential to provide deep and sustained increases in hepcidin and reductions in iron. The data were presented at the European Hematology Association (EHA) 2024 Congress.

Disc Medicine (IRON) Down on Mixed Results From AURORA Study
Zacks Investment Research02 April 2024 Sentiment: NEGATIVE

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire03 January 2024 Sentiment: POSITIVE

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., PhD., President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10th at 2:15 pm PT / 5:15 pm ET.

How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17%
Zacks Investment Research13 November 2023 Sentiment: NEGATIVE

The mean of analysts' price targets for Disc Medicine, Inc. (IRON) points to a 38.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Disc Medicine to Participate in Upcoming Investor Conferences
GlobeNewsWire30 August 2023 Sentiment: NEUTRAL

WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

What type of business is Disc Medicine?

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

What sector is Disc Medicine in?

Disc Medicine is in the Healthcare sector

What industry is Disc Medicine in?

Disc Medicine is in the Biotechnology industry

What country is Disc Medicine from?

Disc Medicine is headquartered in United States

When did Disc Medicine go public?

Disc Medicine initial public offering (IPO) was on 12 August 2020

What is Disc Medicine website?

https://www.discmedicine.com

Is Disc Medicine in the S&P 500?

No, Disc Medicine is not included in the S&P 500 index

Is Disc Medicine in the NASDAQ 100?

No, Disc Medicine is not included in the NASDAQ 100 index

Is Disc Medicine in the Dow Jones?

No, Disc Medicine is not included in the Dow Jones index

When was Disc Medicine the previous earnings report?

No data

When does Disc Medicine earnings report?

The next expected earnings date for Disc Medicine is 08 November 2024